Cell Signaling Technology

Product Pathways - Adhesion

Integrin αV Antibody #4711

Applications Reactivity Sensitivity MW (kDa) Source
W IP H R Endogenous 135, 140 Rabbit

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Integrin αV Antibodies detects endogenous levels of total integrin αV protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg108 of human integrin αV. Antibodies are purified by peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from A549 and C6 cells using Integrin αV Antibody.

Background

Integrins are α/β heterodimeric cell surface receptors that play a pivotal role in cell adhesion and migration, as well as in growth and survival (1,2). The integrin family contains at least 18 α and 8 β subunits that form 24 known integrins with distinct tissue distribution and overlaping ligand specificities (3). Integrins not only transmit signals to cells in response to the extracellular environment (outside-in signaling), but also sense intracellular cues to alter their interaction with extracellular environment (inside-out signaling) (1,2).Several αV subfamily members, including αVβ3, αVβ5, αVβ1, are highly expressed in active endothelial cells and cancer cells (3-6) where they play a critical role in angiogenesis and tumor metastasis (7-9). Therefore, interest has focused on αV integrin as a key therapeutic target in the treatment of cancer (10-12).

  1. Liu, S. et al. (2000) J Cell Sci 113 ( Pt 20), 3563-71.
  2. Hood, J.D. and Cheresh, D.A. (2002) Nat Rev Cancer 2, 91-100.
  3. Koistinen, P. et al. (2004) Int J Cancer 112, 61-70.
  4. Davidson, B. et al. (2003) Gynecol Oncol 90, 248-57.
  5. Schwartz, E.A. et al. (1999) Circ Res 84, 315-22.
  6. Suzuma, K. et al. (1998) Invest Ophthalmol Vis Sci 39, 1028-35.
  7. Eliceiri, B.P. and Cheresh, D.A. (1999) J Clin Invest 103, 1227-30.
  8. Friedlander, M. et al. (1995) Science 270, 1500-2.
  9. Perruzzi, C.A. et al. (2003) J Invest Dermatol 120, 1100-9.
  10. Strieth, S. et al. (2006) Int J Cancer 119, 423-31.
  11. Kumar, C.C. (2003) Curr Drug Targets 4, 123-31.
  12. Tucker, G.C. (2006) Curr Oncol Rep 8, 96-103.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products